Literature DB >> 16205618

Neonatal hypophosphatasia and seizures. A case report.

P Smilari1, D M M Romeo, P Palazzo, C Meli, G Sorge.   

Abstract

Hypophosphatasia is a rare genetic disease characterized by deficiency of tissue-nonspecific alkaline phosphatase (TNSALP) activity, excessive urinary excretion of phosphoethanolamine, poor bone mineralization and skeletal anomalies. The shortage of alkaline phosphatase (ALP) alters the process of mineralization of skeleton causing a reduced transformation of phosphoethanolamine into phosphatidylethanolamine (cerebral phospholipid) with consequent high serum and urinary levels of phosphoethanolamine, a sensitive and highly specific marker for the disease. Four clinical forms have been described based on the age of onset with different courses and prognoses. An unusual case of lethal perinatal hypophosphatasia associated with seizures observed in a newborn admitted to Neonatal Intensive Care Unit of the University of Catania is described.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16205618

Source DB:  PubMed          Journal:  Minerva Pediatr        ISSN: 0026-4946            Impact factor:   1.312


  3 in total

1.  Skeletal mineralization defects in adult hypophosphatasia--a clinical and histological analysis.

Authors:  F Barvencik; F Timo Beil; M Gebauer; B Busse; T Koehne; S Seitz; J Zustin; P Pogoda; T Schinke; M Amling
Journal:  Osteoporos Int       Date:  2011-01-26       Impact factor: 4.507

2.  Infantile hypophosphatasia secondary to a novel compound heterozygous mutation presenting with pyridoxine-responsive seizures.

Authors:  Dina Belachew; Traci Kazmerski; Ingrid Libman; Amy C Goldstein; Susan T Stevens; Stephanie Deward; Jerry Vockley; Mark A Sperling; Arcangela L Balest
Journal:  JIMD Rep       Date:  2013-03-12

Review 3.  Neonatal lethal hypophosphatasia: A case report and review of literature.

Authors:  Laura Castells; Pía Cassanello; Felix Muñiz; María-José de Castro; María L Couce
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.